Major histocompatibility complex, class II, DO beta chain (HLA-DOB)

Major histocompatibility complex, class II, DO beta chain (HLA-DOB) is a membrane-anchored beta chain that forms a heterodimer with an alpha (DOA) chain, collectively termed HLA-DO. This complex plays a regulatory role in the class II antigen presentation pathway of the immune system, being predominantly expressed in antigen-presenting cells such as B lymphocytes, dendritic cells, and macrophages. HLA-DO modulates the peptide loading activity of MHC class II molecules by inhibiting HLA-DM, thereby influencing the repertoire of antigens presented to CD4+ T cells and helping to shape immune responses. While critical to antigen processing and presentation, HLA-DOB is not a primary target for approved therapeutics, nor is it associated with known drug interactions or safety risks as a direct clinical target[1][2][3][5][6][7].

Other names

HLA class II histocompatibility antigen, DO beta chainHLA-DOBMHC class II antigen DOBDOBHLA_DOB

Not applicable (No approved drugs target HLA-DOB directly. Mechanistically, HLA-DOB modulates the function of HLA-DM, which in turn affects peptide exchange on MHC class II, influencing antigen presentation)[7][1][2].